Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced the appointment of Seth Dobrin, Ph.D., to the Company's Scientific Advisory Board (SAB). Dr. Dobrin is the Global Chief Artificial Intelligence (AI) Officer at IBM and brings extensive leadership experience and a track record of transforming companies through data and AI.

"We warmly welcome Seth to our Scientific Advisory Board. Seth is a visionary whose deep experience bringing AI-based business solutions to major global corporations will be invaluable as we continue to develop and augment the AI and machine learning (AIML) capabilities of our PlantSpring^TM platform and BioFactory^TM production system to advance plant-based synthetic biology solutions for important target customers and end markets," said Michael A. Carr, President & CEO of Calyxt.

Mr. Carr added: "We estimate that, aided by machine learning and artificial intelligence, Calyxt will be able to take a customer's molecule need through our design, engineering, verification, and pilot-level production process within a 36-month period, with commercial scale production to commence thereafter. Seth's unique expertise will provide key guidance to us as we develop and further refine our strategy to build our AIML data initiatives and advance our team's skill sets and our capabilities to improve the efficiency and scalability of our offerings. Ultimately, our focus is to help our customers produce more sustainable products and meet corporate sustainability targets."

In his role at IBM, Dr. Dobrin leads the corporate AI strategy. He is responsible for connecting AI development with a systemic creation of business value via a design-driven strategy that enables a transformation of IBM's core operations. Dr. Dobrin leads the effort to fundamentally change every area of IBM, from business operations to product development, by adopting a human-centered approach to AI through a new methodology that he created that ensures continuous and responsible delivery of AI-based business outcomes across the company. Before being appointed as IBM's Global Chief AI Officer, Dr. Dobrin led the digital transformation of IBM's Cloud and Cognitive Software (C&CS) business as Chief Data Officer. Prior to IBM, Dr. Dobrin held roles of increasing responsibility at the Monsanto Company; at the Marshfield Clinic, as the Director for the Center of Medical Genetics; and as a Scientist at the Translational Genomics Research Institute. Dr. Dobrin received a Ph.D. in Molecular and Cellular Biology, and a B.S. in Microbiology from Arizona State University. He is the Chair of the IBM Data Science Procession Board and the co-founder of the women's diversity network, GROW. He serves on the Board of Directors of the Science Center of Iowa and is an adjunct faculty member in the Department of Genetics at Iowa State University.

"I am thrilled to join the Calyxt Scientific Advisory Board at this important time for the Company as it launches its new strategic direction to bring plant-based synthetic biology solutions to global businesses in major industries," said Seth Dobrin, Ph.D. "More precisely, I am impressed by the capabilities that Calyxt has created to deliver unique and innovative plant-based molecules not available through other production methods. By using a data driven approach and by implementing AI and machine learning, Calyxt is well positioned to accelerate its entire process from idea to commercial production. I look forward to advising the Company through its evolution in this exciting new opportunity."

On October 5, 2021, Calyxt announced the launch of a strategic initiative to focus the Company on engineering synthetic biology solutions for a diversified base of customers across an expanded group of end markets, including the nutraceutical, cosmeceutical, pharmaceutical, advanced materials, and chemicals industries. Central to the strategy is the integration of the Company's proprietary technology platform, PlantSpring, with its newly commissioned pilot bioreactor, the BioFactory, which together will enable Calyxt to rapidly prototype and produce complex plant-derived compounds without the need for outdoor cropping systems. Notably, the PlantSpring technology platform leverages an expanding set of AIML capabilities as well as Calyxt's experience, proprietary systems and tools and technologies from more than a decade of engineering plant metabolism.

"We are pleased that Seth has joined our Scientific Advisory Board, where he will bring highly-specialized expertise relevant to the current and future potential of Calyxt. This is a particularly opportune time for Seth to be joining Calyxt as we drive our new strategic initiative, which leverages AIML in important new ways for our customers. We look forward to working with him," said Dan Voytas, Ph.D., Professor in the Department of Genetics, Cell Biology and Development at the University of Minnesota and Chair of the Calyxt SAB.

Calyxt formalized its SAB in March 2021 to provide guidance for Calyxt to leverage and grow the business in new directions and help realize the significant potential value of the Company. The SAB also includes the following members:

• Anne Osbourn, Ph.D., Group Leader at the John Innes Center
• Elizabeth Sattely, Ph.D., HHMI Investigator and Associate Professor of Chemical Engineering, Stanford University
• Paul Bernasconi, Ph.D., Former Global Function Head for Molecular Biology at BASF Biosciences

About the PlantSpring^TM Technology Platform and BioFactory^TM Production System

Calyxt's technology platform, PlantSpring, is built on the Company's experience of more than a decade engineering plant metabolism, its proprietary systems, its tools and technologies, and an expanding set of AIML capabilities. This licensable platform delivers innovation through an efficient process from laboratory to pilot. The process includes identification of breakthrough molecules based on customer needs and design strategies to reprogram host cells; engineering of plant cell metabolism to optimally produce targeted molecules; and production of target molecules at pilot scale. Calyxt has developed early-stage AIML capabilities in PlantSpring, which enable learning and adaptation from knowledge gained from past activity and can be combined with predictive analytics to rapidly prototype and provide feedback, accelerating the time from design to pilot and de-risking the commercial scale-up phase. As a result, Calyxt believes it can develop engineered biomolecules in plants for customers at faster speeds than its competitors in the synthetic biology industry. The output from the PlantSpring platform integrates seamlessly with the Company's newly commissioned BioFactory.

The BioFactory is the culmination of the work of Calyxt's researchers and will enable the Company to expand its production methods from solely outdoor agriculture systems to also include controlled environment, bioreactor-based production systems. The BioFactory harnesses the potential of plant cells in a matrixed structure, combined with nutrients and media for its production, and leverages multiple cell types, without the use of fermentation. The matrix structures enable processing of molecules of increased complexity over traditional fermentation systems and even single cell plant culture methods. In addition, the speed of the matrix growth over time is expected to accelerate the production of the molecule at scale. As a result, Calyxt's process is capable of unlocking the power of plants to produce complex compounds that are finite, difficult to source sustainably, and that likely cannot be produced using other production methods. Initial growth rates using this system have presented a strong productivity curve, with initial results suggesting that Calyxt's plant cells grow more than five times faster compared to other plant-based systems when evaluated in grams per day over a 30-day period. Calyxt's BioFactory is expected to be a sustainable production system with lower levels of off-gasses, waste, and water usage than other synthetic biology production systems.

About Calyxt

Calyxt (Nasdaq: CLXT) is a plant-based synthetic biotechnology company. The Company leverages its proprietary PlantSpring™ technology platform to engineer innovative materials and products for its customers to help them meet their sustainability goals. Calyxt's diversified offerings are delivered through its proprietary BioFactory™ manufacturing process. For more information, visit www.calyxt.com.

PlantSpring, BioFactory and the Calyxt logo are trademarks of Calyxt, Inc. Any other trademarks belong to their respective owners.

Forward-Looking Statements

This communication contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as "anticipates," "believes," "continue," "estimates," "expects," "intends," "may," "might," "plans," "predicts," "projects," "should," "targets," "will," or the negative of these terms and other similar terminology. Forward-looking statements in this press release include statements about our product pipeline and development; our business model and strategies for the development, commercialization and sales of commercial products; commercial demand for our synthetic biology solutions; the development and deployment of our PlantSpring technology platform; our ability to deploy and leverage our AIML capabilities; the ability to scale production capability for our BioFactory; potential collaborations, partnerships, customer relationships, and licensing arrangements and their contribution to our business and results; and anticipated trends in our business. These and other forward-looking statements are predictions and projections about future events and trends based on our current expectations, objectives and intentions and premised on current assumptions. Our actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: the severity and duration of the evolving COVID-19 pandemic and the resulting impact on macro-economic conditions; the impact of increased competition, including competition from a broader array of synthetic biology companies; disruptions at our key facilities, including disruptions impacting our BioFactory; flaws in AIML algorithms, insufficiency of data inputs required by such algorithms, and human error in interacting with AIML; changes in customer preferences and market acceptance of our products; changes in market consensus as to what attributes are required for a product to be considered "sustainable;" competition for collaboration partners and licensees and the successful execution of collaborations and licensing agreements; the impact of adverse events during development, including unsuccessful pilot production of molecules or field trials; the impact of improper handling of our product candidates during development; failures by third-party contractors; inaccurate demand forecasting; the effectiveness of commercialization efforts by commercial partners or licensees; disruptions to supply chains, including raw material inputs for our BioFactory; the impact of changes or increases in oversight and regulation; disputes or challenges regarding intellectual property; proliferation and continuous evolution of new technologies; management changes; dislocations in the capital markets; and other important factors discussed under the caption entitled "Risk Factors" in our Annual Report on Form 10-K and subsequent filings on Form 10-Q or 8-K with the U.S. Securities and Exchange Commission. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.